Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jan. 31, 2013
Jan. 31, 2012
Jan. 31, 2013
Jan. 31, 2012
Revenues:        
Clinical laboratory services $ 13,320 $ 14,123 $ 28,497 $ 28,310
Product revenues 7,876 9,542 16,309 19,245
Royalty and license fee income 1,014 1,308 3,033 3,170
Total revenues 22,210 24,973 47,839 50,725
Operating expenses:        
Cost of clinical laboratory services 9,425 8,709 19,135 17,523
Cost of product revenues 4,143 4,685 8,327 9,822
Research and development 968 1,703 1,979 3,328
Selling, general, and administrative 10,892 11,487 22,308 23,872
Provision for uncollectible accounts receivable 1,335 1,169 2,929 2,455
Legal 1,441 1,023 3,142 1,892
Total operating expenses 28,204 28,776 57,820 58,892
Operating loss (5,994) (3,803) (9,981) (8,167)
Other income (expense):        
Interest (7) 14 (15) 12
Other 43 65 56 76
Foreign currency income (loss) 104 (352) 333 (323)
Loss before income taxes (5,854) (4,076) (9,607) (8,402)
Benefit (provision) for income taxes 180 (145) 242 (313)
Net loss $ (5,674) $ (4,221) $ (9,365) $ (8,715)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.14) $ (0.11) $ (0.24) $ (0.23)
Basic and diluted (in Shares) 39,312 38,616 39,295 38,607